The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).
NPB is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase, which results in toxic...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
